Monitoring CAR T-Cell Therapy Quality with Droplet Digital PCR
The CAR T-cell manufacturing process involves high potential for variability. Learn how sensitive ddPCR assays can be used to ensure safety and efficacy.
CDMOs Drive Cell and Gene Therapy from Behind the Scenes
As more of the cell and gene therapies revolutionizing healthcare are approved for use, innovator companies usually get the credit. But many therapies would never make it to market without the expertise and capabilities of contract development and manufacturing organizations (CDMOs) operating behind the scenes. Learn more about how CDMOs enable new cell and gene therapies to come to market, and how Droplet Digital PCR can help.
Expert Coffee Chats: Coffee Chat #4 – Droplet Digital PCR in Cell and Gene Therapy
Presented by: Matthew L. Turner, PhD, Field Application Scientist – ddPCR, NGC and qPCR, Tara Ellison, PhD, Senior Field Application Scientist
Date: June 17, 2020
Time: 9 AM, U.S. Pacific time
- Robust methodology for viral titer using ddPCR
- Precise copy number determination & improved confidence in acceptance criteria
- Enhance your throughput and minimize hands-on time
- Learn how ddPCR is used in other key applications
A Novel CAR-T Cell Therapy Approach Using Fluorescence-Activated Cell Sorting and Stem Cell Transplantation
Successful chimeric antigen receptor- (CAR-) T cell therapy requires a target antigen that is unique to cancer cells. But what happens when there are no unique antigens? Researchers at Columbia University Medical Center addressed this problem by replacing healthy non-target cells with genetically modified versions lacking the CAR-T cell target. Their results, published in PNAS, may provide a new avenue for treatment of some types of cancer.